GenOway Growth: Analysis of the year 2024 and Outlook 2025

genOway announces a turnover of 22.1 million euros for 2024, representing an organic growth of 10% compared to 2023. This result reflects the stability of genOway's business model despite market challenges. Since 2020, sales staff numbers have been constant, while turnover has doubled. In response to these challenges, genOway plans to triple its sales staff numbers by 2028 as part of its ROUTE50+ strategic plan.

For 2025, genOway intends to strengthen its sales and marketing teams, aiming to double its employees to more effectively penetrate the American and European markets. The company also plans to open in Japan, targeting the fourth largest market in the world for preclinical studies.

genOway remains confident about its EBITDA margin target of over 18% in 2024 and in the long term. CEO Alexandre Fraichard emphasizes that 2025 will be crucial for the company's continued growth strategy, even in challenging market conditions.